Beth Marsh has been appointed as the Chief Commercial Officer of Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, effective April 28, 2025. Beth will take care of the commercial organization, including preparing for the U.S. launch of ENCELTOTM (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
Beth brings a background of commercial and strategic business executive with more than two decades of leadership experience and specialisation in ophthalmology and retina.
“We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,” said Richard Small, Chief Executive Offer. “I am confident that Beth’s expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.”
“This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,” said Beth. “Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of ENCELTO. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.”
Before joining Neurotech, Beth served as Vice President, North America Sales and Marketing in Ophthalmology at Apellis Pharmaceuticals, leading the commercial U.S. launch for SYFOVRE, the first approved treatment for geographic atrophy secondary to age-related macular degeneration. She earlier served in commercial leadership roles at Shire / Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Beth’s earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. Apart from these, she volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University.
About Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases. The core platform technology, Encapsulated Cell Therapy (ECT), is a first-in-class, drug delivery platform designed to slow the progression of Macular Telangiectasia Type 2 (MacTel) and other chronic eye diseases. ENCELTOTM (revakinagene taroretcel-lwey) is approved in the United States for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
About ENCELTOTM
ENCELTO is an encapsulated cell-based gene therapy. It is a small capsule, about the size of a grain of rice, that is placed inside the eye to release a protein called recombinant human ciliary neurotrophic factor (rhCNTF) that can directly reach the retina, the light sensitive part of the eye. The capsule contains living cells that have been genetically modified to continuously produce and release rhCNTF. This protein helps protect certain cells in the retina, supporting their health and reducing the loss of light-sensing cells known as photoreceptors.
ENCELTO is used to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel); a retinal disease that causes progressive vision loss. Your eye surgeon will assess your vision and review your medical history to determine if ENCELTO is the right treatment for you.
